Myriad Genetics price target lowered to $14 from $24 at Piper Sandler
Piper Sandler analyst David Westenberg lowered the firm’s price target on Myriad Genetics (MYGN) to $14 from $24 and keeps a Neutral rating on ...
Cancer Genetic Testing Market Size to Worth USD 17.98 Billion by 2033 | Straits Research
The global cancer genetic testing market size was valued at USD 6.70 billion in 2024 and is projected to reach from USD 7.47 billion in 2025 to USD 17.98 billion by 2033, growing at a CAGR of 11.6% ...
alleywatch.com5h
Nucleus Raises $14M to Transform Genetic Health Testing
AlleyWatch sat down with Nucleus CEO and Founder Kian Sadeghi to learn more about the business, its future plans, and recent ...
labiotech9h
Seven genomics startups to look out for
Discover the top genomics startups revolutionizing genome sequencing technologies to enhance disease prevention and treatment ...
Tal Zaks's Israeli startup targets rare genetic diseases
"This type of gene editing should also allow for the treatment of diseases whose origin is not genetic or whose origin cannot ...
Indiatimes21h
Divis Labs - Divi's Laboratories Share Price
Bonus Sep 23, 2015 Sep 26, 2015 Aug 08, 2015 Bonus Ratio: 1 share(s) for every 1 shares held Bonus Jul 30, 2009 Aug 01, 2009 Jun 06, 2009 Bonus Ratio: 1 share(s) for every 1 shares held Divi's ...